These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 33026049)
1. The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D? Sukkarieh HH; Bustami RT; Abdu MN; Khokhar AA; Salih AA; Abdalla HK Saudi Med J; 2020 Oct; 41(10):1083-1089. PubMed ID: 33026049 [TBL] [Abstract][Full Text] [Related]
2. Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D? Alsaeed A Saudi Med J; 2021 Jan; 42(1):115. PubMed ID: 33399181 [TBL] [Abstract][Full Text] [Related]
3. Estimating the influence of physicians on the underuse of drugs in diabetic nephropathy in Taiwan. Huang LY; Yeh HL; Su S; Wang TC; Hsieh JY J Nephrol; 2013; 26(1):16-24. PubMed ID: 22641577 [TBL] [Abstract][Full Text] [Related]
4. Combination Therapy with Chinese Medicine and ACEI/ARB for the Management of Diabetic Nephropathy: The Promise in Research Fragments. Tu X; Ye X; Xie C; Chen J; Wang F; Zhong S Curr Vasc Pharmacol; 2015; 13(4):526-39. PubMed ID: 25360835 [TBL] [Abstract][Full Text] [Related]
5. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy. Pathak JV; Dass EE Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372 [TBL] [Abstract][Full Text] [Related]
6. Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan. Yeh HL; Huang LY; Su S; Yang MC; Wang TC Health Policy; 2011 May; 100(2-3):196-202. PubMed ID: 21146895 [TBL] [Abstract][Full Text] [Related]
7. Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D? Jawad AS Saudi Med J; 2020 Dec; 41(12):1381. PubMed ID: 33294899 [TBL] [Abstract][Full Text] [Related]
8. Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly. Butt DA; Mamdani M; Gomes T; Lix L; Lu H; Tu K; J Bone Miner Res; 2014 Nov; 29(11):2483-8. PubMed ID: 24806397 [TBL] [Abstract][Full Text] [Related]
9. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154 [TBL] [Abstract][Full Text] [Related]
10. [Assessment of the utilization of angiotensin receptor blockers in hypertension]. Peña Cabia S; Ricote Lobera I; Santos Mena B; Hidalgo Correas FJ; Climent Florez B; García Díaz B Farm Hosp; 2013; 37(5):394-8. PubMed ID: 24128102 [TBL] [Abstract][Full Text] [Related]
11. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311 [TBL] [Abstract][Full Text] [Related]
12. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control. Hunsicker LG J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420 [TBL] [Abstract][Full Text] [Related]
13. Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism. Hu X; Liu W; Yan Y; Liu H; Huang Q; Xiao Y; Gong Z; Du J Eur J Pharmacol; 2019 Feb; 845():91-98. PubMed ID: 30287151 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - A real-world population study in Taiwan. Pai PY; Muo CH; Sung FC; Ho HC; Lee YT Int J Cardiol; 2016 Jul; 215():114-9. PubMed ID: 27111172 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs. Srivastava SP; Goodwin JE; Kanasaki K; Koya D Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32085655 [TBL] [Abstract][Full Text] [Related]
17. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate. Kota SK; Meher LK; Jammula S; Kota SK; Modi KD Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543 [TBL] [Abstract][Full Text] [Related]
18. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy. Ren F; Tang L; Cai Y; Yuan X; Huang W; Luo L; Zhou J; Zheng Y Ren Fail; 2015 May; 37(4):548-61. PubMed ID: 25707526 [TBL] [Abstract][Full Text] [Related]
19. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria. Hsu FY; Lin FJ; Ou HT; Huang SH; Wang CC Kidney Blood Press Res; 2017; 42(2):358-368. PubMed ID: 28618426 [TBL] [Abstract][Full Text] [Related]
20. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols. Bakris GL Postgrad Med; 2003 May; 113(5):35-40, 43-4, 50. PubMed ID: 12764895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]